{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:15:48Z","timestamp":1790244948407,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5188-6","type":"journal-article","created":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T05:39:10Z","timestamp":1546061950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy"],"prefix":"10.1186","volume":"18","author":[{"given":"Robert","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothi Priya","family":"Jagannathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Ramaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco L.","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrajit P.","family":"Raut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Ready","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-9448","authenticated-orcid":false,"given":"Andrew J.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,29]]},"reference":[{"key":"5188_CR1","first-page":"731","volume":"31","author":"HLLL Jaffe","year":"1941","unstructured":"Jaffe HLLL, Sutro CJ. Pigmented villonodular synovitis, bursitis and tenosynovitis. Arch Pathol Lab Med. 1941;31:731\u201365.","journal-title":"Arch Pathol Lab Med"},{"key":"5188_CR2","first-page":"102","volume-title":"World Health Organization classsification of tumors: pathology and genetics of tumors of soft tissue and bone","author":"Somerhausen NS vdRM","year":"2013","unstructured":"Somerhausen NS vdRM. Tenosynovial giant cell tumor, diffuse type. In: BJ FCDM, PCW H, Mertens F, editors. World Health Organization classsification of tumors: pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press; 2013. p. 102\u20133."},{"issue":"2","key":"5188_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","volume":"51","author":"E Palmerini","year":"2015","unstructured":"Palmerini E, Staals EL, Maki RG, Pengo S, Cioffi A, Gambarotti M, Picci P, Daolio PA, Parafioriti A, Morris C, et al. Tenosynovial giant cell tumour\/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. Eur J Cancer. 2015;51(2):210\u20137.","journal-title":"Eur J Cancer"},{"issue":"4","key":"5188_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/00000478-200004000-00002","volume":"24","author":"NS Somerhausen","year":"2000","unstructured":"Somerhausen NS, Fletcher CD. Diffuse-type giant cell tumor: clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease. Am J Surg Pathol. 2000;24(4):479\u201392.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"5188_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1073\/pnas.0507321103","volume":"103","author":"RB West","year":"2006","unstructured":"West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103(3):690\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5188_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/gcc.20501","volume":"47","author":"E Moller","year":"2008","unstructured":"Moller E, Mandahl N, Mertens F, Panagopoulos I. Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors. Genes, chromosomes & cancer. 2008;47(1):21\u20135.","journal-title":"Genes, chromosomes & cancer"},{"issue":"6","key":"5188_CR7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","volume":"31","author":"JS Cupp","year":"2007","unstructured":"Cupp JS, Miller MA, Montgomery KD, Nielsen TO, O'Connell JX, Huntsman D, van de Rijn M, Gilks CB, West RB. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007;31(6):970\u20136.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"5188_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.3892\/ijo.2014.2326","volume":"44","author":"I Panagopoulos","year":"2014","unstructured":"Panagopoulos I, Brandal P, Gorunova L, Bjerkehagen B, Heim S. Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumors. Int J Oncol. 2014;44(5):1425\u201332.","journal-title":"Int J Oncol"},{"issue":"2","key":"5188_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00000478-199702000-00004","volume":"21","author":"F Bertoni","year":"1997","unstructured":"Bertoni F, Unni KK, Beabout JW, Sim FH. Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis). Am J Surg Pathol. 1997;21(2):153\u201363.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"5188_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/PAS.0b013e318158428f","volume":"32","author":"CF Li","year":"2008","unstructured":"Li CF, Wang JW, Huang WW, Hou CC, Chou SC, Eng HL, Lin CN, Yu SC, Huang HY. Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature. Am J Surg Pathol. 2008;32(4):587\u201399.","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"5188_CR11","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.humpath.2014.06.025","volume":"45","author":"N Asano","year":"2014","unstructured":"Asano N, Yoshida A, Kobayashi E, Yamaguchi T, Kawai A. Multiple metastases from histologically benign intraarticular diffuse-type tenosynovial giant cell tumor: a case report. Hum Pathol. 2014;45(11):2355\u20138.","journal-title":"Hum Pathol"},{"key":"5188_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13569-015-0030-2","volume":"5","author":"A Righi","year":"2015","unstructured":"Righi A, Gambarotti M, Sbaraglia M, Frisoni T, Donati D, Vanel D, Dei Tos AP. Metastasizing tenosynovial giant cell tumour, diffuse type\/pigmented villonodular synovitis. Clinical sarcoma research. 2015;5:15.","journal-title":"Clinical sarcoma research"},{"issue":"4","key":"5188_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdn033","volume":"19","author":"JY Blay","year":"2008","unstructured":"Blay JY, El Sayadi H, Thiesse P, Garret J, Ray-Coquard I. Complete response to imatinib in relapsing pigmented villonodular synovitis\/tenosynovial giant cell tumor (PVNS\/TGCT). Ann Oncol. 2008;19(4):821\u20132.","journal-title":"Ann Oncol"},{"issue":"6","key":"5188_CR14","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/cncr.26409","volume":"118","author":"PA Cassier","year":"2012","unstructured":"Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, van der Graaf WT, Italiano A, Seddon B, Domont J, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis. Cancer. 2012;118(6):1649\u201355.","journal-title":"Cancer"},{"issue":"8","key":"5188_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","volume":"16","author":"PA Cassier","year":"2015","unstructured":"Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Muller C, Jegg AM, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. The Lancet Oncology. 2015;16(8):949\u201356.","journal-title":"The Lancet Oncology"},{"issue":"4","key":"5188_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/CCO.0b013e328347e1e3","volume":"23","author":"V Ravi","year":"2011","unstructured":"Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol. 2011;23(4):361\u20136.","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"5188_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, et al. Structure-guided blockade of CSF1R kinase in Tenosynovial Giant-cell tumor. N Engl J Med. 2015;373(5):428\u201337.","journal-title":"N Engl J Med"},{"issue":"2","key":"5188_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11864-015-0385-x","volume":"17","author":"M Brahmi","year":"2016","unstructured":"Brahmi M, Vinceneux A, Cassier PA. Current systemic treatment options for Tenosynovial Giant cell tumor\/pigmented Villonodular synovitis: targeting the CSF1\/CSF1R Axis. Curr Treat Options in Oncol. 2016;17(2):10.","journal-title":"Curr Treat Options in Oncol"},{"key":"5188_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/2156-7514.152343","volume":"5","author":"DM Richman","year":"2015","unstructured":"Richman DM, Bresler SC, Rosenthal MH, Howard SA. Malignant tenosynovial giant cell tumor of the leg: a radiologic-pathologic correlation and review of the literature. Journal of clinical imaging science. 2015;5:13.","journal-title":"Journal of clinical imaging science"},{"issue":"3","key":"5188_CR20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1365-2141.2011.08685.x","volume":"155","author":"K Ullrich","year":"2011","unstructured":"Ullrich K, Wurster KD, Lamprecht B, Kochert K, Engert A, Dorken B, Janz M, Mathas S. BAY 43-9006\/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines. Br J Haematol. 2011;155(3):398\u2013402.","journal-title":"Br J Haematol"},{"issue":"8","key":"5188_CR21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","volume":"20","author":"LJ Murray","year":"2003","unstructured":"Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clinical & experimental metastasis. 2003;20(8):757\u201366.","journal-title":"Clinical & experimental metastasis"},{"issue":"1","key":"5188_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.onc.1209007","volume":"25","author":"JR Taylor","year":"2006","unstructured":"Taylor JR, Brownlow N, Domin J, Dibb NJ. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene. 2006;25(1):147\u201351.","journal-title":"Oncogene"},{"issue":"7","key":"5188_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.4161\/cc.4.7.1788","volume":"4","author":"AL Dewar","year":"2005","unstructured":"Dewar AL, Zannettino AC, Hughes TP, Lyons AB. Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle. 2005;4(7):851\u20133.","journal-title":"Cell Cycle"},{"issue":"8","key":"5188_CR24","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","volume":"105","author":"AL Dewar","year":"2005","unstructured":"Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, Lyons AB. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005;105(8):3127\u201332.","journal-title":"Blood"},{"issue":"3","key":"5188_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, Mestan J, Trappe J, Wartmann M, Fabbro D. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445\u201353.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"5188_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.leu.2404944","volume":"22","author":"N Brownlow","year":"2008","unstructured":"Brownlow N, Russell AE, Saravanapavan H, Wiesmann M, Murray JM, Manley PW, Dibb NJ. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia. 2008;22(3):649\u201352.","journal-title":"Leukemia"},{"issue":"19","key":"5188_CR27","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"S Sleijfer","year":"2009","unstructured":"Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). Journal of clinical oncology. 2009;27(19):3126\u201332.","journal-title":"Journal of clinical oncology"},{"issue":"6","key":"5188_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","volume":"15","author":"P Hamberg","year":"2010","unstructured":"Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15(6):539\u201347.","journal-title":"Oncologist"},{"issue":"9829","key":"5188_CR29","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT Graaf van der","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schoffski P, Aglietta M, Staddon AP, Beppu Y, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879\u201386.","journal-title":"Lancet"},{"issue":"3","key":"5188_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00005792-198005000-00004","volume":"59","author":"BWMA Myers","year":"1980","unstructured":"Myers BWMA. Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review. Medicine (Baltimore). 1980;59(3):223\u201338.","journal-title":"Medicine (Baltimore)"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5188-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5188-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5188-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T19:08:28Z","timestamp":1577560108000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5188-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5188"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5188-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"20 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of Dana-Farber Cancer Institute and Brigham and Women\u2019s Hospital. Written informed consent to publish their clinical data was obtained from each patient before the initiation of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients prospectively provided signed informed consent for an Institutional Review Board-approved protocol for research use of medical records, of pathologic specimens obtained as part of routine clinical care, and publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AJW; Consulting: Five Prime, Eli Lilly, Loxo Research Funding to the institution: Five Prime, Daiichi-Sankyo, Plexxikon, Eli Lilly, Karyopharm, AADi.*The other authors do not have any competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1296"}}